Comparative cellular pharmacokinetics and pharmacodynamics of siRNA delivery by SPANosomes and by cationic liposomes

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 4, 2013, Pages 504-513

  Zhou, Chenguang ^a   Zhang, Yue ^a,b   Yu, Bo ^a,c   Phelps, Mitch A ^a   Lee, L James ^a,c   Lee, Robert J ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b CHINESE ACADEMY OF INSPECTION AND QUARANTINE   (China)

^c Ohio State University   (United States)

Author keywords

Cellular pharmacokinetics; Intracellular trafficking; Nanoparticle; RNA interference; SiRNA

Indexed keywords

FLUORESCENCE INTENSITIES; INTRACELLULAR TRAFFICKING; PHARMACOKINETIC PROFILES; PHARMACOKINETICS AND PHARMACODYNAMICS; RNA INTERFERENCE; SIRNA; SMALL INTERFERING RNA; SMALL INTERFERING RNA (SIRNA);

CYTOLOGY; FLOW CYTOMETRY; NANOPARTICLES; PHARMACOKINETICS;

RNA;

CATIONIC LIPOSOME; LIPOSOME; METFORMIN; NANOCARRIER; SMALL INTERFERING RNA; SPANOSOME; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; IC 50; MOLECULAR BEACON; PARTICLE SIZE; PHARMACODYNAMICS; QUANTITATIVE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL;

AREA UNDER CURVE; BASE SEQUENCE; CATIONS; CELL LINE; DNA PRIMERS; GENE SILENCING; HUMANS; LIPOSOMES; RNA, SMALL INTERFERING;

EID: 84876714850     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.10.002     Document Type: Article

References (45)

1. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006, 2:711-719.
2. Dykxhoorn D.M., Palliser D., Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006, 13:541-552.
3. Kim A., Lee E.H., Choi S.H., Kim C.K. In vitro and in vivo transfection efficiency of a novel ultradeformable cationic liposome. Biomaterials 2004, 25:305-313.
4. Kim S.S., Garg H., Joshi A., Manjunath N. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol Med 2009, 15:491-500.
5. Zhou C., Mao Y., Sugimoto Y., et al. SPANosomes as delivery vehicles for small interfering RNA (siRNA). Mol Pharm 2012, 9:201-210.
6. Lu J.J., Langer R., Chen J. A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. Mol Pharm 2009, 6:763-771.
7. Zhou F., Zhang J., Li P., et al. Toward a new age of cellular pharmacokinetics in drug discovery. Drug Metab Rev 2011, 43:335-345.
8. Chen H.H., Ho Y.P., Jiang X., Mao H.Q., Wang T.H., Leong K.W. Quantitative comparison of intracellular unpacking kinetics of polyplexes by a model constructed from quantum dot-FRET. Mol Ther 2008, 16:324-332.
9. Parra-Guillen Z.P., Gonzalez-Aseguinolaza G., Berraondo P., Troconiz I.F. Gene therapy: a pharmacokinetic/pharmacodynamic modelling overview. Pharm Res 2010, 27:1487-1497.
10. Heyes J., Palmer L., Bremner K., MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 2005, 107:276-287.
11. Breunig M., Hozsa C., Lungwitz U., et al. Mechanistic investigation of poly(ethylene imine)-based siRNA delivery: disulfide bonds boost intracellular release of the cargo. J Control Release 2008, 130:57-63.
12. Akita H., Ito R., Khalil I.A., Futaki S., Harashima H. Quantitative three-dimensional analysis of the intracellular trafficking of plasmid DNA transfected by a nonviral gene delivery system using confocal laser scanning microscopy. Mol Ther 2004, 9:443-451.
13. Hama S., Akita H., Ito R., Mizuguchi H., Hayakawa T., Harashima H. Quantitative comparison of intracellular trafficking and nuclear transcription between adenoviral and lipoplex systems. Mol Ther 2006, 13:786-794.
14. Nitin N., Rhee W.J., Bao G. Translation inhibition reveals interaction of 2'-deoxy and 2'-O-methyl molecular beacons with mRNA targets in living cells. Nucleic Acids Res 2009, 37:4977-4986.
15. Boukany P.E., Morss A., Liao W.C., et al. Nanochannel electroporation delivers precise amounts of biomolecules into living cells. Nat Nanotechnol 2011, 6:747-754.
16. Zhou C., Yu B., Yang X., et al. Lipid-coated nano-calcium-phosphate (LNCP) for gene delivery. Int J Pharm 2010, 392:201-208.
17. Kaneda M.M., Sasaki Y., Lanza G.M., Milbrandt J., Wickline S.A. Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials 2010, 31:3079-3086.
18. Yu B., Hsu S.H., Zhou C., et al. Lipid nanoparticles for hepatic delivery of small interfering RNA. Biomaterials 2012, 33:5924-5934.
19. Wang P., Henning S.M., Heber D. Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS One 2010, 5:e10202.
20. Akita H., Kogure K., Moriguchi R., et al. Nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J Control Release 2010, 143:311-317.
21. Sen G.L., Blau H.M. Argonaute 2/RISC resides in sites of mammalian mRNA decay known as cytoplasmic bodies. Nat Cell Biol 2005, 7:633-636.
22. Zhou C., Mao Y., Lee L.J., Lee R.J. Quantitative analysis of intracellular and cytoplasmic siRNA delivery by SPANosomes. AAPS J 2010, 12. Abstract T2073.
23. Zhou C., Lee L.J., Lee R.J. Cellular pharmacokinetics (PK) and target gene knockdown of surfactant- and lipid-based nanocarriers (NCs) of siRNA. AAPS J 2011, 13. Abstract W3028.
24. Alousi A.M., Boinpally R., Wiegand R., et al. A phase 1 trial of XK469: toxicity profile of a selective topoisomerase IIbeta inhibitor. Invest New Drugs 2007, 25:147-154.
25. Zhang Y., Zhou C., Kwak K.J., et al. Efficient siRNA delivery using a polyamidoamine dendrimer with a modified pentaerythritol core. Pharm Res 2012, 29:1627-1636.
26. Banks G.A., Roselli R.J., Chen R., Giorgio T.D. A model for the analysis of nonviral gene therapy. Gene Ther 2003, 10:1766-1775.
27. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
28. Zhou C., Zhang Y., Lee L.J., Lee R.J. Novel lipoidal amine-based nanocarrier formulations for siRNA delivery. Therapeutic Delivery. 2012, 3:715-723.
29. Juliano R., Alam M.R., Dixit V., Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008, 36:4158-4171.
30. Bartlett D.W., Davis M.E. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res 2006, 34:322-333.
31. Zhang Y., Li H., Sun J., et al. DC-Chol/DOPE cationic liposomes: A comparative study of the influence factors on plasmid pDNA and siRNA gene delivery. Int J Pharm 2010.
32. Semple S.C., Akinc A., Chen J., et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010, 28:172-176.
33. Overhoff M., Wunsche W., Sczakiel G. Quantitative detection of siRNA and single- stranded oligonucleotides: relationship between uptake and biological activity of siRNA. Nucleic Acids Res 2004, 32:e170.
34. Bartlett D.W., Davis M.E. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng 2007, 97:909-921.
35. Hacker M., Messer W.S., Bachmann K.A. Pharmacology: principles and practice 2009, 239-240.
36. Rejman J., Bragonzi A., Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol Ther 2005, 12:468-474.
37. Zuhorn I.S., Kalicharan R., Hoekstra D. Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis. J Biol Chem 2002, 277:18021-18028.
38. Khalil I.A., Kogure K., Akita H., Harashima H. Uptake pathways and subsequent intracellular trafficking in nonviral gene delivery. Pharmacol Rev 2006, 58:32-45.
39. Love K.T., Mahon K.P., Levins C.G., et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 2010, 107:1864-1869.
40. Ferrari A., Pellegrini V., Arcangeli C., Fittipaldi A., Giacca M., Beltram F. Caveolae- mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol Ther 2003, 8:284-294.
41. Lai S.K., Hida K., Man S.T., et al. Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. Biomaterials 2007, 28:2876-2884.
42. Rejman J., Oberle V., Zuhorn I.S., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J 2004, 377:159-169.
43. Akinc A., Zumbuehl A., Goldberg M., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008, 26:561-569.
44. Akinc A., Querbes W., De S., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010, 18:1357-1364.
45. Zhou C., Shen P., Cheng Y. Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells. Biochim Biophys Acta 2007, 1770:1011-1020.